Day Two

• SNAP-TI is an ASIT platform that enables co-delivery of multiple unique peptide antigens and rapamycin in nanoparticles of precise size and composition for local (IM or SC) administration
• VTP-1000 is a candidate for celiac disease based on SNAP-TI
• Updates on the VTP-1000 clinical program including safety and immunology parameters will be presented

• Engineered vaccine variants that target antigens to defined immune cell subsets, triggering the immune system in distinct directions depending on which APC that receive the antigen
• Tune immune outcomes to drive preferential effects on autoantibodies, regulatory T cells, and effector cells achieving a level of control unmatched in the field
• Compare versions across sophisticated transgenic models to precisely measure cytokine responses in low-frequency cell populations and define disease-specific immune modulation

NEW DATA

• Exploring the mechanisms by which EVOQ Therapeutics’ nanoparticles induce antigen-specific immune tolerance, using multiple preclinical animal models to dissect the immunological pathways and molecular interactions underlying therapeutic efficacy
• Validating novel biomarkers to monitor immune tolerance in both preclinical and clinical contexts, establishing robust readouts that can inform translational studies and support the predictive value of preclinical models
• Discover how preclinical mechanistic insights and biomarker development can accelerate the translation of nanoparticle-based immune tolerance therapies into clinical trials, providing predictive frameworks for celiac disease and other immune-mediated conditions

• Explores T-cell subsets beyond B-cell depletion—particularly tissue-resident memory, follicular helper, and peripheral helper T cells—as key drivers of autoimmune persistence and B-cell activation
• Examines evidence that selective depletion or modulation of these T-cell and myeloid populations may deliver deep, durable disease control comparable to B-cell–targeted approaches
• Addresses translational challenges including efficient tissue-level depletion, optimizing delivery and biodistribution of therapeutic modalities, and defining biomarkers that capture local immune modulation

• Ahead MiMiTOPs display a broad, cross-disease mechanism of action
• Antigen-presenting cells from patients with T1D, RA, MG, MS and iTTP acquire a tolerogenic phenotype following interaction with MiMiTOPs. Dendritic cells and macrophages become tolerogenic, reducing their ability to drive autoreactive T cell proliferation, while B lymphocytes directly internalize MiMiTOPs and secrete TGF-β and IL-10, adopting an immunoregulatory phenotype
• Through coordinated effects on innate and adaptive immunity, MiMiTOPs provide an antigen-specific strategy to support long-term immune tolerance

NEW DATA

• Introduction to TargetScan, a cell-based, unbiased platform that pairs naturally presented antigens with their cognate TCRs
• Demonstrating TargetScan’s ability to identify both CD8⁺ and CD4⁺ T cell targets in example indications such as ankylosing spondylitis, birdshot uveitis, scleroderma, and ulcerative colitis
• Exploring novel biologically validated targets that enable antigen-specific tolerizing therapies in indications such as ankylosing spondylitis

• Highlighting a platform-centric gene editing strategy that harmonizes clinical protocols and manufacturing processes, allowing a single target modification to be applied across multiple autoimmune indications
• Showcasing a multi-indication clinical development pathway that leverages Phase I safety and mechanistic insights to accelerate Phase II expansion, streamlining translation across diverse disease contexts

NEW DATA

• Thymology 101: How the thymus shapes the T cell repertoire by induction of potent and durable Tregs and deletion of autoreactive Tconv cells
• Zag Bio’s biologics-based approach to target systemically administered antigens to the thymus for restoration of immune homeostasis
• Demonstration of tissue-specific bystander suppression in autoimmune disease models

• Exploring the thymus – the central organ responsible for establishing and maintaining immune tolerance
• Development of iPSC – derived thymic cells that demonstrate in vivo T cell education to re-establish central tolerance in immune-related diseases
• Unlocking the potential of thymus – based regenerative medicine to restore immune balance